Pear Therapeutics (Pear Therapeutics) EV-to-Revenue

: -1.71 (As of Today)

View and export this data going back to 2021. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Pear Therapeutics's enterprise value is $-21.65 Mil. Pear Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $12.69 Mil. Therefore, Pear Therapeutics's EV-to-Revenue for today is -1.71.

The historical rank and industry rank for Pear Therapeutics's EV-to-Revenue or its related term are showing as below:

PEARQ's EV-to-Revenue is not ranked ^*
in the Healthcare Providers & Services industry.
Industry Median: 1.78
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-23), Pear Therapeutics's stock price is $0.0001. Pear Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.09. Therefore, Pear Therapeutics's PS Ratio for today is 0.00.

Pear Therapeutics EV-to-Revenue Historical Data

The historical data trend for Pear Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

168.01

11.35

Pear Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EV-to-Revenue	Get a 7-Day Free Trial							168.01	90.81	16.69	20.83	11.35

Competitive Comparison

For the Health Information Services subindustry, Pear Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pear Therapeutics EV-to-Revenue Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's EV-to-Revenue falls into.

Pear Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Pear Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-21.651	/	12.694
	=	-1.71

Pear Therapeutics's current Enterprise Value is $-21.65 Mil.
Pear Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.69 Mil.

Pear Therapeutics (OTCPK:PEARQ) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Pear Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0001	/	0.089
	=	0.00

Pear Therapeutics's share price for today is $0.0001.
Pear Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.09.

Pear Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Pear Therapeutics (Pear Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 State Street, 13th Floor, Boston, MA, USA, 02109

Website

https://www.peartherapeutics.com

Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.

Executives

5am Partners Iv, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner	officer: Chief Product Dev. Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg	officer: Chief Commercial Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien	officer: General Counsel & Secretary	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey	director, officer: President and CEO	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich	officer: Chief Medical Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow	officer: Chief Accounting Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre	officer: CFO, COO, Treas., & Asst. Sec.	65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery	officer: Chief People Officer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks	director	C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman	director	6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc	10 percent owner	195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch	director	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd.	10 percent owner	60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891